Cigarette smoking causes oral inflammation, dental caries, and gingival hyperpigmentation, thereby impairing oral health and self-confidence. This study evaluated the potential of standardized Cyanthillium cinereum extract (SCCE) in oral health promotion, focusing on its anti-inflammatory, cytoprotective, antibacterial, and anti-tyrosinase activities. SCCE was prepared using microwave-assisted extraction and standardized to contain high levels of apigenin and luteolin contents. Anti-inflammatory effects were assessed in murine macrophages by measuring nitric oxide scavenging activity and the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and tumor necrosis factor-α (TNF-α). Cytoprotective activity was evaluated in human gingival fibroblasts exposed to H₂O₂. Antibacterial activity against Streptococcus mutans was tested using disc diffusion method, while tyrosinase inhibitory activity was examined using enzymatic assays. SCCE effectively scavenged nitric oxide (IC50 of 189.20 mg/mL) and significantly suppressed iNOS, COX-2, and TNF-α expression in macrophages. Its activity was comparable to apigenin and luteolin, and in some assays superior to indomethacin. SCCE also protected gingival fibroblasts from H₂O₂-induced cell death, with cell viability up to 57.29 - 73.66%, though its cytotoxicity profile varied by cell type. However, SCCE demonstrated no antibacterial activity against S. mutans at 1 mg/disc and showed no significant tyrosinase inhibition. SCCE exhibits strong anti-inflammatory and cytoprotective effects, supporting its potential as a natural oral healthcare product for smokers. Despite its limited antibacterial and tyrosinase inhibitory activities, its anti-inflammatory and antioxidative properties highlight its promise in mitigating smoking-related oral health problems. Further clinical studies and prototype formulation development are warranted to advance its application.
Background: Oral collagen supplements are widely marketed for improving skin aging parameters, however, high‐quality clinical evidence for multi‐ingredient formulations in Asian populations remains limited. Aims: This study evaluated the safety and efficacy of a hydrolyzed collagen formulation (HYCOS) on facial skin parameters in healthy Thai volunteers. Methods: A 12‐week double‐blind, randomized placebo‐controlled trial was conducted in 140 Thai participants aged 30–60 with mild‐to‐moderate facial wrinkles. Participants were received either HYCOS collagen (hydrolyzed collagen with Glutathione and Vitamin E) or a placebo drink. Skin hydration, elasticity, and crow's feet wrinkle roughness were measured using Corneometer, Cutometer, and 3D skin imaging (PRIMOS CR ), respectively. Dermatologist wrinkle grading and participant self‐assessment were collected. Safety was evaluated through adverse event monitoring and blood/urine biochemical testing. Results: A total of 135 participants completed the study (test product, n = 66; placebo, n = 69). After 12 weeks, both groups showed significant increases in skin hydration ( p < 0.001), with no between‐group difference. The test product group demonstrated greater improvements in skin elasticity; gross elasticity (R2), net elasticity (R5), and overall elasticity (R7) compared with placebo ( p < 0.05). Crow's feet wrinkle roughness analysis revealed significantly greater reductions in wrinkle roughness in the test product group than in the placebo group at week 12. No product‐related adverse events were observed, and laboratory values remained within normal ranges. Conclusion: Daily supplementation with HYCOS collagen formula for 12 weeks was safe and well tolerated, with significant improvements in skin elasticity and wrinkle roughness. Increases in skin hydration were observed in both groups, suggesting that this effect may be influenced by hydration‐related or behavioural factors rather than the supplement alone. Overall, HYCOS supplementation may provide beneficial effects on skin aging parameters in healthy adults. Trial Registration: Thai Clinical Trials Registry: TCTR20250619006